Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Assistant Professor in Radiation Oncology
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994


Blackwell, K, Gligorov, J, Jacobs, I, and Twelves, C. "The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer." Clinical Breast Cancer 18, no. 2 (April 1, 2018): 95-113. (Review)

Full Text

Force, J, Howie, LJ, Abbott, SE, Bentley, R, Marcom, PK, Kimmick, G, Westbrook, K, Sammons, SL, Parks, M, Topping, DL, Emerson, R, Broadwater, G, Hyslop, T, Blackwell, KL, and Nair, SK. "Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype." Clinical breast cancer (February 24, 2018).

Full Text

Harbeck, N, Gascón, P, Krendyukov, A, Hoebel, N, Gattu, S, and Blackwell, K. "Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies (Accepted)." Oncologist (January 1, 2018).

Full Text

Blackwell, K, Gascon, P, Krendyukov, A, Gattu, S, Li, Y, and Harbeck, N. "Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy." Annals of oncology : official journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 244-249.

Full Text

Shammas, RL, Cho, EH, Glener, AD, Poveromo, LP, Mundy, LR, Greenup, RA, Blackwell, KL, and Hollenbeck, ST. "Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis." Journal of the American College of Surgeons 225, no. 6 (December 2017): 731-739.e1.

Full Text

Narloch, JL, Farber, SH, Sammons, S, McSherry, F, Herndon, JE, Hoang, JK, Yin, F-F, Sampson, JH, Fecci, PE, Blackwell, KL, Kirkpatrick, JP, and Kim, GJ. "Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis." Neuro-oncology 19, no. 10 (October 2017): 1391-1397.

Full Text

Ma, CX, Bose, R, Gao, F, Freedman, RA, Telli, ML, Kimmick, G, Winer, E, Naughton, M, Goetz, MP, Russell, C, Tripathy, D, Cobleigh, M, Forero, A, Pluard, TJ, Anders, C, Niravath, PA, Thomas, S, Anderson, J, Bumb, C, Banks, KC, Lanman, RB, Bryce, R, Lalani, AS, Pfeifer, J, Hayes, DF, Pegram, M, Blackwell, K, Bedard, PL, Al-Kateb, H, and Ellis, MJC. "Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 19 (October 2017): 5687-5695.

Full Text

Blackwell, K, Gascon, P, Jones, CM, Nixon, A, Krendyukov, A, Nakov, R, Li, Y, and Harbeck, N. "Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer." Annals of oncology : official journal of the European Society for Medical Oncology 28, no. 9 (September 2017): 2272-2277.

Full Text

Harbeck, N, Gascon, P, Jones, CM, Nixon, A, Krendyukov, A, Nakov, R, Li, Y, and Blackwell, K. "Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials." Future oncology (London, England) 13, no. 16 (July 2017): 1385-1393.

Full Text

Diéras, V, Miles, D, Verma, S, Pegram, M, Welslau, M, Baselga, J, Krop, IE, Blackwell, K, Hoersch, S, Xu, J, Green, M, and Gianni, L. "Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial." The Lancet. Oncology 18, no. 6 (June 2017): 732-742.

Full Text